Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Morganroth, J
   Focus on issues in measuring and interpreting changes in the QTc interval duration
   EUROPEAN HEART JOURNAL SUPPLEMENTS
   
   J. Morganroth, "Focus on issues in measuring and interpreting changes in the QTc interval duration", EUR H J SUP, 3(K), 2001, pp. K105-K111
2. Kaemmerer, WF; Rose, MS; Mehra, R
   Distribution of patients' paroxysmal atrial tachyarrhythmia episodes: Implications for detection of treatment efficacy
   JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY
   
   W.F. Kaemmerer et al., "Distribution of patients' paroxysmal atrial tachyarrhythmia episodes: Implications for detection of treatment efficacy", J CARD ELEC, 12(2), 2001, pp. 121-130
3. Stallard, N; Whitehead, J; Todd, S; Whitehead, A
   Stopping rules for phase II studies
   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
   
   N. Stallard et al., "Stopping rules for phase II studies", BR J CL PH, 51(6), 2001, pp. 523-529
4. Phillips, CV
   The economics of 'more research is needed'
   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
   
   C.V. Phillips, "The economics of 'more research is needed'", INT J EPID, 30(4), 2001, pp. 771-776
5. MacArthur, RD; Chen, L; Mayers, DL; Besch, CL; Novak, R; van den Berg-Wolf, M; Yurik, T; Peng, G; Schmetter, B; Brizz, B; Abrams, D
   The rationale and design of the CPCRA (Terry Beirn Community Programs for Clinical Research on AIDS) 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies) trial
   CONTROLLED CLINICAL TRIALS
   
   R.D. MacArthur et al., "The rationale and design of the CPCRA (Terry Beirn Community Programs for Clinical Research on AIDS) 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies) trial", CONTR CL TR, 22(2), 2001, pp. 176-190
6. Dowlati, A; Crosby, L; Remick, SC; Makkar, V; Levitan, N
   Paclitaxel added to the cisplatin/etoposide regimen in extensive-stage small cell lung cancer - the use of complete response rate as the primary endpoint in phase II trials
   LUNG CANCER
   
   A. Dowlati et al., "Paclitaxel added to the cisplatin/etoposide regimen in extensive-stage small cell lung cancer - the use of complete response rate as the primary endpoint in phase II trials", LUNG CANC, 32(2), 2001, pp. 155-162
7. Thall, PF; Sung, HG; Choudhury, A
   Dose-finding based on feasibility and toxicity in T-cell infusion trials
   BIOMETRICS
   
   P.F. Thall et al., "Dose-finding based on feasibility and toxicity in T-cell infusion trials", BIOMETRICS, 57(3), 2001, pp. 914-921
8. Claxton, K; Lacey, LF; Walker, SG
   Selecting treatments: a decision theoretic approach
   JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES A-STATISTICS IN SOCIETY
   
   K. Claxton et al., "Selecting treatments: a decision theoretic approach", J ROY STA A, 163, 2000, pp. 211-225
9. Kaptchuk, TJ; Goldman, P; Stone, DA; Stason, WB
   Do medical devices have enhanced placebo effects?
   JOURNAL OF CLINICAL EPIDEMIOLOGY
   
   T.J. Kaptchuk et al., "Do medical devices have enhanced placebo effects?", J CLIN EPID, 53(8), 2000, pp. 786-792
10. Stadler, WM; Ratain, MJ
    Development of target-based antineoplastic agents
    INVESTIGATIONAL NEW DRUGS
    
    W.M. Stadler e M.J. Ratain, "Development of target-based antineoplastic agents", INV NEW DR, 18(1), 2000, pp. 7-16
11. Machado, SG; Murray, GD; Teasdale, GM
    Evaluation of designs for clinical trials of neuroprotective agents in head injury
    JOURNAL OF NEUROTRAUMA
    
    S.G. Machado et al., "Evaluation of designs for clinical trials of neuroprotective agents in head injury", J NEUROTRAU, 16(12), 1999, pp. 1131-1138
12. Cronin, KA; Freedman, LS; Lieberman, R; Weiss, HL; Beenken, SW; Kelloff, GJ
    Bayesian monitoring of Phase II trials in cancer chemoprevention
    JOURNAL OF CLINICAL EPIDEMIOLOGY
    
    K.A. Cronin et al., "Bayesian monitoring of Phase II trials in cancer chemoprevention", J CLIN EPID, 52(8), 1999, pp. 705-711
13. Heasman, PA; McCraken, GI
    Powered toothbrushes: a review of clinical trials
    JOURNAL OF CLINICAL PERIODONTOLOGY
    
    P.A. Heasman e G.I. McCraken, "Powered toothbrushes: a review of clinical trials", J CLIN PER, 26(7), 1999, pp. 407-420
14. Morris, GF; Bullock, R; Marshall, SB; Marmarou, A; Maas, A; Marshall, LF
    Failure of the competitive N-methyl-D-aspartate antagonist Selfotel (CGS 19755) in the treatment of severe head injury: results of two Phase III clinical trials
    JOURNAL OF NEUROSURGERY
    
    G.F. Morris et al., "Failure of the competitive N-methyl-D-aspartate antagonist Selfotel (CGS 19755) in the treatment of severe head injury: results of two Phase III clinical trials", J NEUROSURG, 91(5), 1999, pp. 737-743
15. Stallard, N; Thall, PF; Whitehead, J
    Decision theoretic designs for phase II clinical trials with multiple outcomes
    BIOMETRICS
    
    N. Stallard et al., "Decision theoretic designs for phase II clinical trials with multiple outcomes", BIOMETRICS, 55(3), 1999, pp. 971-977
16. RICHARDSON D; LEURGANS S
    SAMPLE-SIZE JUSTIFICATION IN PHASE III IV CLINICAL-TRIALS/
    Neuroepidemiology
    
    D. Richardson e S. Leurgans, "SAMPLE-SIZE JUSTIFICATION IN PHASE III IV CLINICAL-TRIALS/", Neuroepidemiology, 17(2), 1998, pp. 63-66
17. AZEN SP; PETERS RK; BERKOWITZ K; KJOS S; XIANG A; BUCHANAN TA
    TRIPOD (TROGLITAZONE IN THE PREVENTION OF DIABETES) - A RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF TROGLITAZONE IN WOMEN WITH PRIOR GESTATIONAL DIABETES-MELLITUS
    Controlled clinical trials
    
    S.P. Azen et al., "TRIPOD (TROGLITAZONE IN THE PREVENTION OF DIABETES) - A RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF TROGLITAZONE IN WOMEN WITH PRIOR GESTATIONAL DIABETES-MELLITUS", Controlled clinical trials, 19(2), 1998, pp. 217-231
18. BEYDOUN A; FISCHER J; LABAR DR; HARDEN C; CANTRELL D; UTHMAN BM; SACKELLARES JC; ABOUKHALIL B; RAMSAY RE; HAYES A; GREINER M; GAROFALO E; PIERCE M
    GABAPENTIN MONOTHERAPY .2. A 26-WEEK, DOUBLE-BLIND, DOSE-CONTROLLED, MULTICENTER STUDY OF CONVERSION FROM POLYTHERAPY IN OUTPATIENTS WITH REFRACTORY COMPLEX PARTIAL OR SECONDARILY GENERALIZED SEIZURES
    Neurology
    
    A. Beydoun et al., "GABAPENTIN MONOTHERAPY .2. A 26-WEEK, DOUBLE-BLIND, DOSE-CONTROLLED, MULTICENTER STUDY OF CONVERSION FROM POLYTHERAPY IN OUTPATIENTS WITH REFRACTORY COMPLEX PARTIAL OR SECONDARILY GENERALIZED SEIZURES", Neurology, 49(3), 1997, pp. 746-752
19. BIALER M; JOHANNESSEN SI; KUPFERBERG HJ; LEVY RH; LOISEAU P; PERUCCA E
    PROGRESS REPORT ON NEW ANTIEPILEPTIC DRUGS - A SUMMARY OF THE 3RD EILAT CONFERENCE
    Epilepsy research
    
    M. Bialer et al., "PROGRESS REPORT ON NEW ANTIEPILEPTIC DRUGS - A SUMMARY OF THE 3RD EILAT CONFERENCE", Epilepsy research, 25(3), 1996, pp. 299-319
20. SHERIDAN PH; JACOBS MP
    THE DEVELOPMENT OF ANTIEPILEPTIC DRUGS FOR CHILDREN - REPORT FROM THENIH WORKSHOP, BETHESDA, MARYLAND, FEBRUARY 17-18, 1994
    Epilepsy research
    
    P.H. Sheridan e M.P. Jacobs, "THE DEVELOPMENT OF ANTIEPILEPTIC DRUGS FOR CHILDREN - REPORT FROM THENIH WORKSHOP, BETHESDA, MARYLAND, FEBRUARY 17-18, 1994", Epilepsy research, 23(1), 1996, pp. 87-92
21. SCHULMAN KA; GLICK H; BUXTON M; SCULPHER M; BACKHOUSE M; BELL L; EISENBERG JM
    THE ECONOMIC-EVALUATION OF THE FIRST STUDY - DESIGN OF A PROSPECTIVE ANALYSIS ALONGSIDE A MULTINATIONAL PHASE-III CLINICAL-TRIAL
    Controlled clinical trials
    
    K.A. Schulman et al., "THE ECONOMIC-EVALUATION OF THE FIRST STUDY - DESIGN OF A PROSPECTIVE ANALYSIS ALONGSIDE A MULTINATIONAL PHASE-III CLINICAL-TRIAL", Controlled clinical trials, 17(4), 1996, pp. 304-315
22. WHITLEY RJ; GNANN JW; WEISS HL; SOONG SJ
    UNIQUE CLINICAL-TRIAL DESIGN - COMBINATION ACYCLOVIR PLUS PREDNISONE THERAPY OF LOCALIZED ZOSTER IN THE NORMAL HOST
    Antiviral research
    
    R.J. Whitley et al., "UNIQUE CLINICAL-TRIAL DESIGN - COMBINATION ACYCLOVIR PLUS PREDNISONE THERAPY OF LOCALIZED ZOSTER IN THE NORMAL HOST", Antiviral research, 29(1), 1996, pp. 67-68
23. REICHELDERFER PS; COOMBS RW
    CARTESIAN COORDINATE ANALYSIS OF VIRAL BURDEN AND CD4- IMPLICATIONS FOR CLINICAL-TRIAL DESIGN AND ANALYSIS( CELL COUNT IN HIV DISEASE )
    Antiviral research
    
    P.S. Reichelderfer e R.W. Coombs, "CARTESIAN COORDINATE ANALYSIS OF VIRAL BURDEN AND CD4- IMPLICATIONS FOR CLINICAL-TRIAL DESIGN AND ANALYSIS( CELL COUNT IN HIV DISEASE )", Antiviral research, 29(1), 1996, pp. 83-86
24. SABERS A; GRAM L
    DRUG-TREATMENT OF EPILEPSY IN THE 1990S - ACHIEVEMENTS AND NEW DEVELOPMENTS
    Drugs
    
    A. Sabers e L. Gram, "DRUG-TREATMENT OF EPILEPSY IN THE 1990S - ACHIEVEMENTS AND NEW DEVELOPMENTS", Drugs, 52(4), 1996, pp. 483-493
25. ROTHENBERG ML; ABBRUZZESE JL; MOORE M; PORTENOY RK; ROBERTSON JM; WANEBO HJ
    A RATIONALE FOR EXPANDING THE END-POINTS FOR CLINICAL-TRIALS IN ADVANCED PANCREATIC-CARCINOMA
    Cancer
    
    M.L. Rothenberg et al., "A RATIONALE FOR EXPANDING THE END-POINTS FOR CLINICAL-TRIALS IN ADVANCED PANCREATIC-CARCINOMA", Cancer, 78(3), 1996, pp. 627-632
26. STABLES JP; BIALER M; JOHANNESSEN SI; KUPFERBERG HJ; LEVY RH; LOISEAU P; PERUCCA E
    PROGRESS REPORT ON NEW ANTIEPILEPTIC DRUGS A SUMMARY OF THE 2ND EILAT-CONFERENCE
    Epilepsy research
    
    J.P. Stables et al., "PROGRESS REPORT ON NEW ANTIEPILEPTIC DRUGS A SUMMARY OF THE 2ND EILAT-CONFERENCE", Epilepsy research, 22(3), 1995, pp. 235-246
27. HOLFORD NHG; WILLIAMS PEO; MUIRHEAD GJ; MITCHELL A; YORK A
    POPULATION PHARMACODYNAMICS OF ROMAZARIT
    British journal of clinical pharmacology
    
    N.H.G. Holford et al., "POPULATION PHARMACODYNAMICS OF ROMAZARIT", British journal of clinical pharmacology, 39(3), 1995, pp. 313-320
28. THALL PF; SIMON R
    A BAYESIAN-APPROACH TO ESTABLISHING SAMPLE-SIZE AND MONITORING CRITERIA FOR PHASE-II CLINICAL-TRIALS
    Controlled clinical trials
    
    P.F. Thall e R. Simon, "A BAYESIAN-APPROACH TO ESTABLISHING SAMPLE-SIZE AND MONITORING CRITERIA FOR PHASE-II CLINICAL-TRIALS", Controlled clinical trials, 15(6), 1994, pp. 463-481
29. BROWN RH; LYNCH M; LEEF D; GUNSBY J; LOBER K; MOORE K; STEPKA C; VELATHOMAS A; GAASTERLAND DE; COYLE E; HUNDLEY M; ASHBURN F; VAYER L; MICHELITSCH K; LAUBER S; BURT E; RAE A; WEBER PA; DERICK R; MCKINNEY K; MOORE D; BAKER ND; KAPETANSKY F; LEHMAN D; GLOECKNER B; SHARF LJ; ROMANS B; SATTERWHITE Y; SIMMONS L; HARBIN TS; OZMENT RR; WRIGHT J; BUTLER L; LASALLE J; PERRY M; NUMMERDOR D; WILLE L; ECKEL A; SESSION C; MARTIN A; CYRLIN MN; FAZIO R; WILENSKY JT; LINDENMUTH K; NAIL CA; RATHBONE D; GATES V; TADELMAN M; SONTY S; HOPKINS G; HIGGINBOTHAM EJ; SCHOLES G; UVA R; PAPPAS L; FROHLICHSTEIN D; FIENE J; BERGSTROM TJ; LICHTER PR; STANDARDI C; ZIEHMSCOTT J; PAPIERNIAKDUBIEL R; POLLACKRUNDLE C; SKUTA GL; BEESON C; CREW RP; KRUSEKE L; MICHAEL B; DEDERIAN J; WICKER D; AARON D; BIRK J; VANHECK T; ALLEN RC; NEWMAN SA; NORLUND JR; FENDLEY CK; BERGHUIS C; CHISHOLM J; EVANS C; MURPHY E; SCHOTT LJ; FORNILI R; SCHWARTZ AL; WEISS H; WEHRLY S; PAPPAS S; ODEA M; BOECKL A; LOPEZ P; CARMODY K; MERCER R; MONKS V; VAWTER K; WITOL CV; CIRONE M; GURLEY J; REED C; BROWNING J; HARRIS E; KATZ LJ; SPAETH GL; WILSON RP; SAMUEL F; BLOCK A; KAO S; BEKERSHOFF CC; CAPRIOLI J; MILLER E; ROCHE M; GROTTOLE G; LEONE A; TRESSLER C; EDERER F; SULLIVAN EK; WAGNER EL; ENTLER G; BRADFORD M; TOMLIN KL; STINE E; LINDBLAD AS; KNOKE JD; DENEKAS M; SMITH C; VOSS T; MOWERY RL; LYNCH G; GOFF F; FURBERG CD; CONNETT JE; DAVIS MD; DUEKER DK; GREEN SB; HAMILTON MP; SCHNEIDERMAN MA; KASSOFF A; MORRIS M; PALMBERG PF
    THE ADVANCED GLAUCOMA INTERVENTION STUDY (AGIS) .1. STUDY DESIGN AND METHODS AND BASE-LINE CHARACTERISTICS OF STUDY PATIENTS
    Controlled clinical trials
    
    R.H. Brown et al., "THE ADVANCED GLAUCOMA INTERVENTION STUDY (AGIS) .1. STUDY DESIGN AND METHODS AND BASE-LINE CHARACTERISTICS OF STUDY PATIENTS", Controlled clinical trials, 15(4), 1994, pp. 299-325
30. SCHOENFELD DA; FINKELSTEIN DM; RICHMAN DD
    DESIGNING PHASE-II STUDIES OF CHEMOTHERAPY FOR HIV-INFECTION USING CD4 AS AN END-POINT
    AIDS
    
    D.A. Schoenfeld et al., "DESIGNING PHASE-II STUDIES OF CHEMOTHERAPY FOR HIV-INFECTION USING CD4 AS AN END-POINT", AIDS, 7(7), 1993, pp. 955-958
31. TANG DI; GELLER NL; POCOCK SJ
    ON THE DESIGN AND ANALYSIS OF RANDOMIZED CLINICAL-TRIALS WITH MULTIPLE END-POINTS
    Biometrics
    
    D.I. Tang et al., "ON THE DESIGN AND ANALYSIS OF RANDOMIZED CLINICAL-TRIALS WITH MULTIPLE END-POINTS", Biometrics, 49(1), 1993, pp. 23-30